Vor Biopharma Inc. VOR
Set alert
19.68 USD -1.23 -5.88%
At close · Oct 30
19.75 +0.07 +0.36%
After hours · Oct 30, 5:12 PM ET
19.37 Day range 20.47
6.86 52-week range 25.10
- YTD
- +50.46%
- 1 year
- -21.28%
- Open
- 19.91
- Prev close
- 20.91
- Mkt cap
- 1.07B
- Vol
- 759.60K
- Avg vol
- 952.59K
- EPS
- 180.18
- P/E
- 0.11
- Div yield
- 0.00%
More statistics
- Low
- 19.37
- High
- 20.47
- Forward P/E
- -5.36
- Beta
- 1.78
- Short ratio
- 5.69
- Inst. own
- 86.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 25, 2027
- 50-d avg
- 20.82
- 200-d avg
- 17.31
- 1y target
- 39.00
6M chart
Events in this range
- May 13, 2026Earnings: -0.73; estimate -0.75; surprise 2.67%
- May 14, 2026Rating: Wedbush · Neutral → Neutral
- May 18, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Aug 11, 2026Earnings: -1.16; estimate -0.69; surprise -68.12%
- Aug 12, 2026Rating: Wedbush · Neutral → Neutral
- Oct 21, 2026Rating: William Blair · — → Outperform
- Oct 30, 2026Earnings: -0.9; estimate -1.14; surprise 21.05%
Signals (47)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bearish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 29, 2026 | 3 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| SMA: Bearish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 8, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| RSI: Overbought | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| RSI: Overbought | Jul 2, 2026 | 4 months ago |
| RSI: Overbought | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| SMA: Bearish | Jun 24, 2026 | 4 months ago |
| SMA: Bearish | Jun 24, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 18, 2026 | 4 months ago |
| SMA: Bearish | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | Jun 17, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| SMA: Bearish | May 22, 2026 | 5 months ago |
| SMA: Bearish | May 22, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| SMA: Bullish | May 5, 2026 | 6 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | May 1, 2026 | 6 months ago |
Key statistics
- Market cap
- 1.07B
- Enterprise value
- 773.83M
- Trailing P/E
- 0.11
- Forward P/E
- -5.36
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 180.18
- Beta
- 1.78
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -79.50M
- Total cash
- 466.13M
- Total debt
- 2.88M
- Return on equity
- 0.00%
- Shares outstanding
- 54.19M
- Short % of float
- 14.81%
- 50-day average
- 20.82
- 200-day average
- 17.31
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 39.00 +98.2% upside
Now 19.68
- Target (low)
- 27.00
- Target (mean)
- 39.00
- Target (high)
- 50.00
Ratings (0m) 10 9 buy · 1 hold · 0 sell
- Strong buy1
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 25, 2027
Expected Mar 25, 2027. Consensus EPS estimate -0.77.
Financials — quick view
VOR Revenue — quarterly 0
VOR Net income — quarterly -86.73M
VOR EPS — quarterly -1.45
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 25, 2027 | Mar 30, 2027 | -0.94707 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | -1.14 | -0.90 | +0.24 | +21.05% |
| Aug 11, 2026 | Jun 30, 2026 | -0.69 | -1.16 | -0.47 | -68.12% |
| May 13, 2026 | Mar 31, 2026 | -0.75 | -0.73 | +0.02 | +2.67% |
| Mar 30, 2026 | Dec 31, 2025 | -1.14 | 44.50 | +45.64 | +4,003.51% |
| Nov 13, 2025 | Sep 30, 2025 | -3.06 | -121.63 | -118.57 | -3,874.84% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | William Blair | init | — | Outperform |
| Aug 12, 2026 | Wedbush | main | Neutral | Neutral |
| May 18, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2026 | Wedbush | main | Neutral | Neutral |
| Apr 15, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 31, 2026 | Wedbush | main | Neutral | Neutral |
About Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vorbio.com
News
- Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint
- Vor Bio Announces Data Phase 3 Trial Of Telitacicept By Its RemeGen Partner Demonstrates Over 95% Participants Achieved At Least 5-Point MG-ADL Improvement Over 48 Weeks
- Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday
- Microsoft To $500? Here Are 10 Top Analyst Forecasts For Wednesday
- Oxford Industries Posts Q4 Results, Joins ADMA Biologics, Vor Biopharma And Other Big Stocks Moving Higher On Friday
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Market-Moving News for December 9th
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Your note
Sign in to keep a note on VOR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANG ROBERT M.D. | Chief Executive Officer | Stock Award(Grant) | Feb 2, 2025 | 921,739 |
| ATTAR EYAL C | Officer | Sale | Feb 12, 2025 | 126,625 |
| CHAKRABORTY TIRTHA | Officer | Stock Award(Grant) | Feb 2, 2025 | 221,272 |
| CHOI HAN WOOK | Chief Financial Officer | Stock Award(Grant) | Feb 2, 2025 | 52,500 |
| MAHATME SANDESH | Chief Financial Officer | Stock Award(Grant) | Jul 8, 2025 | 13,882,800 |
| RA CAPITAL HEALTHCARE FUND,L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 23, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 9.59% | 5,673,078 | 111.65M | Jun 29, 2026 |
| FMR, LLC | 8.34% | 4,932,149 | 97.06M | Jun 29, 2026 |
| FCPM III Services B.V. | 6.96% | 4,117,354 | 81.03M | Jun 29, 2026 |
| Blackrock Inc. | 5.86% | 3,468,107 | 68.25M | Jun 29, 2026 |
| Venrock Adviser, LLC | 5.14% | 3,041,719 | 59.86M | Jun 29, 2026 |
| State Street Corporation | 4.42% | 2,616,336 | 51.49M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.62% | 1,550,885 | 30.52M | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.37% | 1,399,605 | 27.54M | Aug 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.15% | 1,270,144 | 25.00M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.85% | 1,091,626 | 21.48M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.68% | 996,334 | 19.61M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 1.10% | 650,678 | 12.81M | Jul 30, 2026 |